Article 4 Amendment to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001

After paragraph 3 of Part II of the Schedule (which specifies controlled drugs excepted from Part I)^f1 insert—

“4.

A liquid formulation—

(a)

containing a botanical extract of cannabis—

(i)

with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and

(ii)

where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,

(b)

which is dispensed through a metered dose pump as a mucosal mouth spray, and

(c)

which was approved for marketing by the Medicines and Healthcare products Regulatory Agency on 16^th June 2010^f2”